Life science GPI 4Planet ™
Proven skin benefits sustainably crafted
Thanks to a patented biotechnological process, we have now made available an active ingredient whose efficacy and safety has been amply documented by authoritative international experimental and clinical studies: glycerophosphoinositol, a molecule present physiologically in our body (autocoid) and with proven soothing and anti-inflammatory activity. Used in numerous cosmetic formulations and in dermatology, it is under development for pharmaceutical indications in collaboration with Dr.ssa Corda and her research team.
A strong scientific foundation and an innovative process and product improvement, also for the benefit of the planet.
Glycerophosphoinositol (GPI) choline salt is an innovative plant-based active ingredient covered by an international patent and obtained today, with biotechnological processes, from sunflower lecithin. GPI has anti-inflammatory activity in several areas, and its efficacy and safety are recognized and documented by authoritative international studies. The new process eliminates the use of solvents altogether and significantly reduces energy consumption and the use of resources such as water and soil, thanks to the use of an alternative enzymatic conversion process to the one used to date.
Application in dermatology
Atopic dermatitis, irritant dermatitis, allergic dermatitis, and seborrheic dermatitis and related symptoms. Periods of suspension from corticosteroid and/or anti-inflammatory therapy. Solar erythema or from other external agents. Dermatological physical and chemical treatments (e.g. post-laser). Skin irritations (e.g. in diaper rash).
Application in cosmetics
Skin care: anti-aging and prevention of photo-aging and post-inflammatory pigmentation. Body care: for sensitive and inflamed skin. Sun protection (sun care) and after sun. Hair care: for dandruff, seborrheic dermatitis, even accompanied by itching.
Possible formulations
Emulsions, Lotions, Eye drops, Mouthwash, Oral Spray, Dental Care, Vaginal Douches.
A sustainable approach for effective soothing action.
GPI is produced physiologically in the body (autocoid) as a precursor of the synthesis of phospholipids in cell membranes and belongs to a family of compounds capable of modulating and negatively regulating the activation of the cytosolic phospholipase A2 enzyme (cPLA2). This enzyme is the main responsible for the release of arachidonic acid, precursor of the main pro-inflammatory chemical mediators, such as prostaglandins, thromboxanes and leukotrienes, capable of activating and feeding the cellular inflammatory processes and tissue damage.
Negative feedback system.
GPI, the final product of a metabolic pathway, regulates upstream enzymatic activity through a negative feedback system. An excessive increase in arachidonic acid, caused by inflammatory stimuli, increases GPI levels, activating the autoregulatory mechanism and limiting the activity of the cPLA2 enzyme, thus reducing the inflammatory process. The exogenous administration of GPI therefore uses this negative feedback mechanism on cPLA2. In vitro studies conducted by Daniela Corda at the Mario Negri Sud Institute have shown that GPI inhibits the release of arachidonic acid induced by the activation of phospholipase A2.
A physiological and safe mechanism of action.
The effect of GPI occurs upstream of the inhibition of cyclooxygenase and lipoxygenase, unlike nonsteroidal anti-inflammatory drugs (NSAIDs) and leukotriene receptor antagonists. This approach allows for a soothing and anti-inflammatory activity comparable to that of low-to-medium-efficacy corticosteroids, but with an improved safety profile, since its highly hydrophilic structure prevents interaction with steroid receptors and makes it usable daily.